Advanced Pipeline, Aggressive Timeline

At Anji, we focus on high-value, innovative projects that have been credentialed by human data. With a lean operational model that avoids bureaucracy and red tape, we can pursue the best ideas at the right time and work quickly and efficiently to help patients across the globe.

We Focus on What Works

Our custom-built portfolio prioritizes unmet need, without limitations on disease area or therapeutic modality.

Molecule

ANJ900 MetDR

Pre-clinical

Phase 1

Phase 2

Phase 3

ANJ908 Pradigastat

ANJ028 ApoE Mimetic

What’s Happening at Anji

Anji Pharma Acquires Global Development Rights for ApoE Mimetic Peptides from LipimetiX

Anji Pharmaceuticals Acquires Late-Stage Clinical Asset and Readies for Ph3 Trials in Type 2 Diabetes with Chronic Kidney Disease

Anji Pharma Secures China Rights to Apo E Mimetic Platform from LipimetiX Development

Advanced Pipeline, Aggressive Timeline

We Focus on What Works

What’s Happening at Anji

For partnerships, investment opportunities, or to learn more about our work, contact us.